Send to:

Choose Destination
See comment in PubMed Commons below
Reprod Toxicol. 2005 May-Jun;20(1):175-8.

Levetiracetam use and pregnancy outcome.

Author information

  • 1Department of Medical Genetics, University Medical Centre Utrecht, PO Box 85090, 3508 AB Utrecht, The Netherlands.


Prenatal exposure to levetiracetam (LEV) has been shown to cause skeletal abnormalities and growth retardation in animal studies, but the teratogenicity of this new antiepileptic drug in humans is still unknown. We detected no malformations in a series of 11 pregnancies with LEV exposure, although it was striking that three cases had a low birth weight. There may be an association between maternal LEV use and reduced birth weight, but too few cases have been monitored so far. We recommend that the outcomes of all pregnancies exposed to LEV should be carefully registered.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk